Menu Close

Global Stem cell therapy Market 2018-2025 Consumption, Export, Import by Regions, Competitors, Pricing Strategy, Brand Strategy

An exclusive Stem cell therapy Market research report created through broad primary research (inputs from industry experts, companies, and stakeholders) and secondary research, the report aims to present the analysis of Global Stem cell therapy Market By …

Date : 2018-07-26T22:05:00.000Z
Source : https://empowerednews.net/global-stem-cell-therapy-market-2018-2025-consumption-export-import-by-regions-competitors-pricing-strategy-brand-strategy/181251811/

Gene Therapy for Sickle-Cell Diseases| a Drug Pipeline Analysis Report 2018| Technavio

LONDON–(BUSINESS WIRE)–Technavio has announced their latest pipeline analysis report on gene therapy for sickle-cell diseases. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period …

Date : 2018-07-25T22:44:00.000Z
Source : https://www.businesswire.com/news/home/20180725005688/en/Gene-Therapy-Sickle-Cell-Diseases-Drug-Pipeline-Analysis

Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy

James Sherley heads a biotechnology company that offers a technology-enabled service to the fields of stem cell research, stem cell regenerative medicine, and drug discovery. Asymmetrex offers the first-in-kind technology for specific counting of adult …

Date : 2018-07-24T14:32:00.000Z
Source : http://www.bio-medicine.org/biology-news-1/Asymmetrex-Proposes–u201CStemgene-Therapy-u201D-to-Emphasize-the-Importance-of-Tissue-Stem-Cells-for-Successful-Gene-Therapy-39224-1/

GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK

GlaxoSmithKline plc and Adaptimmune Therapeutics plc ADAP, -2.61% a leader in T-cell therapy to treat cancer, today announced the transition of the development program for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, to GSK. As a result of the …

Date : 2018-07-25T00:31:00.000Z
Source : https://www.marketwatch.com/press-release/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-program-to-gsk-2018-07-24